Metastatic Colorectal Cancer

Adding panitumumab to FOLFOXIRI chemotherapy improved rates of overall response and secondary resection of metastases among patients with RAS wild-type metastatic colorectal cancer, according to results of the randomized phase 2 VOLFI trial published in Journal of Clinical Oncology.

BARCELONA, Spain — Triplet therapy with encorafenib, cetuximab and binimetinib significantly extended OS compared with standard treatment for patients with BRAF V600E mutation-positive metastatic colorectal cancer, according to results of the phase 3 BEACON CRC trial presented at European Society for Medical Oncology Congress.

Patients with metastatic colorectal cancer who exercised regularly achieved longer PFS than those who did not, according to results of a companion study to the Cancer and Leukemia Group B/SWOG 80305 trial published in Journal of Clinical Oncology.